These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38035037)

  • 1. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
    Miller M; Bhatt DL; Brinton EA; Jacobson TA; Steg PG; Pineda AL; Ketchum SB; Doyle RT; Tardif JC; Ballantyne CM
    Eur Heart J Open; 2023 Nov; 3(6):oead114. PubMed ID: 38035037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
    Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM;
    J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.
    Miller M; Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Ballantyne CM; Budoff M; Mason RP
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):129-137. PubMed ID: 35953437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
    Verma S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Dhingra NK; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Mason RP; Tardif JC; Ballantyne CM;
    Circulation; 2021 Dec; 144(23):1845-1855. PubMed ID: 34710343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM
    Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    Circulation; 2021 Jan; 143(1):33-44. PubMed ID: 33148016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
    Bhatt DL; Miller M; Brinton EA; Jacobson TA; Steg PG; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Olshansky B; Chung MK; Gibson CM; Giugliano RP; Budoff MJ; Ballantyne CM;
    Circulation; 2020 Feb; 141(5):367-375. PubMed ID: 31707829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
    Olshansky B; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Kowey PR; Reiffel JA; Tardif JC; Ballantyne CM; Chung MK;
    J Am Heart Assoc; 2023 Mar; 12(5):e026756. PubMed ID: 36802845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
    Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
    Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
    Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ;
    Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):488-499. PubMed ID: 38678009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
    Derington CG; Bress AP; Herrick JS; Fan W; Wong ND; Andrade KE; Johnson J; Philip S; Abrahamson D; Jiao L; Bhatt DL; Weintraub WS
    Am J Prev Cardiol; 2022 Jun; 10():100345. PubMed ID: 35574517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
    Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM;
    Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry.
    Picard F; Bhatt DL; Ducrocq G; Ohman EM; Goto S; Eagle KA; Wilson PWF; Smith SC; Elbez Y; Steg PG
    Int J Cardiol; 2021 Oct; 340():96-104. PubMed ID: 34450192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.